[Ultraearly treatment on sudden deafness and the influence on superoxide dismutase and malonyldialdehyde of serum].
OBJECTIVE
To explore the effect of treatment on sudden deafness at ultra-early stage and the influence on Malonyldialdehyde (MDA) and superoxide dismutase(SOD) of serum.


METHODS
One hundred and forty-seven cases of sudden deafness (168 ears) from July 1995 to June 2001 were divided into three groups, 29 cases (36 ears) in group I treated within 6 hours after deafness, 55 cases(63 ears) in group II treated within 15 days after deafness, and 63 cases (69 ears) in group III treatment after 15 days after deafness. Total cases were treated with medicine and hyperbaric oxygen and the volume of SOD and MDA of serum were observed at the same time. There were 30 healthy volunteers as control group.


RESULTS
In the group I, the hearing threshold was recovered in 18 ears, significant improved in 9 ears, improved in 7 ears and not changed in 2 ears after treatment. In the group II, the hearing threshold was recovered in 11 ears, significant improved in 16 ears, improved in 15 ears and no changed in 21 ears after treatment. In the group III, the hearing threshold was recovered in 14 ears, significant improved in 20 ears, improved in 13 ears and no changed in 22 ears after treatment. There was a significant difference in improved level of hearing between the group I and group II. (chi 2 = 9.90, P < 0.01) and between group I and group III (chi 2 = 9.30, P < 0.01). There was no significant difference between group II and group III (chi 2 = 0.03, P > 0.01).


CONCLUSIONS
The treatment on sudden deafness in ultra-early stage is very important. The use of free radical scavenger early can protect audio nerve.
Wang
Weiguo
W
Department of Otorhinolaryngology, Overseas Chinese Federation Hospital of Shandong, Zibo 255031, China. Kongjie-yu@263.net
Xu
Rong
R
Yao
Maojun
M
D000328:Adult; D003131:Combined Modality Therapy; D005260:Female; D003639:Hearing Loss, Sudden / Q000097:blood / Q000628:therapy*; D006801:Humans; D006931:Hyperbaric Oxygenation; D008297:Male; D008315:Malondialdehyde / Q000097:blood*; D008875:Middle Aged; D009553:Nimodipine / Q000627:therapeutic use; D013482:Superoxide Dismutase / Q000097:blood*
D008315:Malondialdehyde; D009553:Nimodipine; D013482:Superoxide Dismutase